Over a 21-month period, 70 ICU patients at Barnes-Jewish Hospital in St. Louis were followed to determine if a commonly administered probiotic could prevent gastrointestinal colonization of multi-drug resistant, infection-causing bacteria such as Clostridium difficile or Enterococcus.
The researchers found no significant difference in overall acquisition of any potentially harmful organisms between a group given probiotics and a control group. However, the study was confined to lower intestinal bacteria and did not assess any impact there may have been on bacteria in the stomach or upper airways.
More articles on infection control:
10 most-read infection control stories in August
Want to avoid a cold? Get more sleep, study finds
CDC confirms 11 plague cases since April: 5 things to know
